ID   MCF-7/TPT300
AC   CVCL_4V42
SY   MCF7/TPT300
DR   cancercelllines; CVCL_4V42
DR   Wikidata; Q54904395
RX   PubMed=10930538;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:63632; Topotecan.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0031 ! MCF-7
SX   Female
AG   69Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 05-10-23; Version: 13
//
RX   PubMed=10930538; DOI=10.1016/S0006-2952(00)00396-8;
RA   Yang C.-H., Schneider E., Kuo M.-L., Volk E.L., Rocchi E., Chen Y.-C.;
RT   "BCRP/MXR/ABCP expression in topotecan-resistant human breast
RT   carcinoma cells.";
RL   Biochem. Pharmacol. 60:831-837(2000).
//